Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Clin Pharmacol ; 65(4): 531-9, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18294327

ABSTRACT

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * Voriconazole, a broad-spectrum antifungal drug, is a substrate and inhibitor of CYP2C19 and CYP3A4 isozymes. * Ethinyl oestradiol and norethindrone, components of the combination oral contraceptive drug Ortho-Novum 1/35, also are substrates of cytochrome P450 CYP2C19 and CYP3A4 isozymes. * Because co-administration of voriconazole and Ortho-Novum 1/35 could potentially result in pharmacokinetic interactions that increase systemic exposure of one or both drugs to unsafe levels, clinical studies are needed to define better the two-way pharmacokinetic interaction between these drugs. WHAT THIS STUDY ADDS: * Although co-administered voriconazole and oral contraceptive did result in increased systemic exposures of all three drugs relative to respective monotherapy, co-administered treatment was generally safe and well tolerated. * It is recommended, however, that patients receiving co-administered voriconazole and oral contraceptives be monitored for the development of adverse events commonly associated with these medications. AIM: To assess the two-way pharmacokinetic interaction between voriconazole and Ortho-Novum 1/35, an oral contraceptive containing norethindrone 1 mg and ethinyl oestradiol 35 microg. METHODS: In this open-label, three-period, fixed-sequence study, 16 healthy females received voriconazole (400 mg q12 h, day 1; 200 mg q12 h, days 2-4) (period 1), oral contraceptive (q24 h, days 12-32) (period 2), and combination voriconazole (400 mg q12 h, day 57; 200 mg q12 h, days 58-60) and oral contraceptive (q24 h, days 40-60) (period 3). RESULTS: Voriconazole geometric mean AUC(tau) and C(max) increased 46% (12 682-18 495 ng h ml(-1); 90% confidence interval [CI] 32, 61) and 14% (2485-2840 ng ml(-1); 90% CI 3, 27), respectively, when co-administered with oral contraceptive vs. voriconazole alone. Ethinyl oestradiol geometric mean AUC(tau) and C(max) increased 61% (1031-1657 ng h ml(-1); 90% CI 50, 72) and 36% (119-161 ng ml(-1); 90% CI 28, 45), respectively, and norethindrone geometric mean AUC(tau) and C(max) increased 53% (116-177 ng h ml(-1); 90% CI 44, 64) and 15% (18-20 ng ml(-1); 90% CI 3, 28), respectively, during voriconazole co-administration vs. oral contraceptive alone. Neither ethinyl oestradiol nor norethindrone levels were reduced in subjects following voriconazole co-administration. Adverse events (AEs) were generally mild, occurring less in subjects receiving voriconazole alone (36 events) vs. oral contraceptive alone (88 events) or combination treatment (68 events); four subjects experienced a severe AE. CONCLUSIONS: Co-administration of voriconazole and oral contraceptive increased systemic exposures of all analytes relative to respective monotherapy. Although generally safe and well tolerated, it is recommended that patients receiving co-administered voriconazole and oral contraceptive be monitored for development of AEs commonly associated with these medications.


Subject(s)
Antifungal Agents/pharmacokinetics , Aryl Hydrocarbon Hydroxylases/metabolism , Contraceptives, Oral, Combined/pharmacokinetics , Cytochrome P-450 CYP3A/metabolism , Mixed Function Oxygenases/metabolism , Pyrimidines/pharmacokinetics , Triazoles/pharmacokinetics , Adolescent , Adult , Antifungal Agents/administration & dosage , Antifungal Agents/adverse effects , Contraceptives, Oral, Combined/administration & dosage , Contraceptives, Oral, Combined/adverse effects , Cytochrome P-450 CYP2C19 , Dose-Response Relationship, Drug , Drug Interactions/physiology , Epidemiologic Methods , Female , Humans , Isoenzymes , Mass Spectrometry/methods , Pyrimidines/administration & dosage , Pyrimidines/adverse effects , Treatment Outcome , Triazoles/administration & dosage , Triazoles/adverse effects , Voriconazole
2.
J Clin Pharmacol ; 48(1): 73-84, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18025525

ABSTRACT

A randomized, placebo-controlled (with respect to voriconazole), 2-period, multiple-dose intragroup fixed-dose sequence study was conducted in 34 healthy male subjects to evaluate the interactions between voriconazole (triazole antifungal agent) and efavirenz (reverse transcriptase inhibitor). In period 1, subjects received 200 mg twice-daily (bid) voriconazole (n = 17) or placebo (n = 17) for 3 days (400-mg bid loading doses on day 1). In period 2, following a 7-day washout, subjects received 400 mg once-daily (qd) efavirenz alone for 10 days (days 11-20). Then efavirenz was coadministered with 200 mg bid voriconazole or placebo for the next 9 days (days 21-29). Serial plasma voriconazole and efavirenz concentrations were measured on days 3, 19, and 29, and the safety data were collected throughout the study. The 400-mg qd efavirenz dose substantially reduced the steady-state mean voriconazole area under the curve over the dosing interval (AUC0-12) by 80% (90% confidence interval [CI], 75%-84%) and peak concentration (Cmax) by 66% (90% CI, 57%-73%). The decrease in voriconazole exposure during coadministration is probably mainly due to the induction of CYP2C19 and CYP2C9 by efavirenz. The 200 mg bid voriconazole increased the steady-state mean AUC0-24 and Cmax of efavirenz by 43% (90% CI, 36%-51%) and 37% (90% CI, 29%-46%), respectively. The increase in efavirenz exposure during coadministration is probably due to the inhibition of CYP3A4 by voriconazole. Coadministration of 200 mg bid voriconazole with 400 mg (or higher) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics.


Subject(s)
Benzoxazines/pharmacokinetics , Pyrimidines/pharmacokinetics , Triazoles/pharmacokinetics , Adolescent , Adult , Age Factors , Alkynes , Antifungal Agents/adverse effects , Antifungal Agents/pharmacokinetics , Area Under Curve , Benzoxazines/adverse effects , Body Weight , Capsules , Creatine Kinase/blood , Cyclopropanes , Drug Interactions , Heart Block/chemically induced , Humans , Male , Metabolic Clearance Rate , Middle Aged , Pyrimidines/adverse effects , Reverse Transcriptase Inhibitors/adverse effects , Reverse Transcriptase Inhibitors/pharmacokinetics , Rhabdomyolysis/chemically induced , Tablets , Triazoles/adverse effects , Voriconazole
3.
Antimicrob Agents Chemother ; 51(10): 3617-26, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17646413

ABSTRACT

Since there is a likelihood of coadministration of voriconazole and ritonavir, two studies were conducted to evaluate the potential of drug interaction. Study A was a randomized, placebo-controlled, two-period, parallel-group trial (n = 34). Study B had the same design without the placebo group (n = 17). In period 1, subjects received 200 mg voriconazole or placebo twice daily (BID) for 3 days (400 mg BID on day 1). In period 2, following a 7-day washout, subjects received ritonavir alone at 400 mg BID (study A) or 100 mg BID (study B) for 10 days (days 11 to 20), and then ritonavir was coadministered with 200 mg BID voriconazole or placebo for the next 10 days (days 21 to 30). Serial plasma samples were collected on days 3, 20, and 30, and safety data were collected throughout the study. High-dose (400 mg BID) ritonavir substantially reduced the steady-state mean voriconazole exposure (area under the concentration-time curve from 0 to 12 h [AUC(0-12)], -82%; maximum concentration [C(max)], -66%). However, the effect of low-dose (100 mg BID) ritonavir was less pronounced (AUC(0-12), -39%; C(max), -24%). The decrease in voriconazole exposure was probably due to the induction of CYP2C19 and CYP2C9 by ritonavir. It is interesting that one subject in each study exhibited the opposite effect of ritonavir on voriconazole exposure (a 2.5- to 3-fold increase), probably due to lack of CYP2C19. Voriconazole had no apparent effect on the exposure of high-dose ritonavir but slightly decreased the exposure of low-dose ritonavir (AUC(0-12), -14%; C(max), -24%). The safety profile of combination therapy was not notably different from that of voriconazole or ritonavir alone. Due to the significant effect of ritonavir on voriconazole exposure, coadministration of voriconazole with 400 mg BID ritonavir is contraindicated; coadministration with 100 mg BID ritonavir should be avoided, unless an assessment of the benefit/risk to the patient justifies the use.


Subject(s)
Anti-HIV Agents/pharmacokinetics , Antifungal Agents/adverse effects , Antifungal Agents/pharmacokinetics , Pyrimidines/adverse effects , Pyrimidines/pharmacokinetics , Ritonavir/adverse effects , Ritonavir/pharmacokinetics , Triazoles/adverse effects , Triazoles/pharmacokinetics , Adult , Anti-HIV Agents/adverse effects , Antifungal Agents/administration & dosage , Area Under Curve , Drug Interactions , Humans , Male , Middle Aged , Pyrimidines/administration & dosage , Ritonavir/administration & dosage , Sample Size , Triazoles/administration & dosage , Voriconazole
4.
Antimicrob Agents Chemother ; 51(1): 110-8, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17074798

ABSTRACT

This trial was aimed to estimate the pharmacokinetic interaction between voriconazole and methadone at steady state in male patients on methadone therapy and to characterize the safety and tolerability profile during the coadministration. Twenty-three patients on individualized methadone therapy (30 to 100 mg once daily) were enrolled into this randomized, patient- and investigator-blind, placebo-controlled, parallel-group study. Methadone pharmacokinetic samples were collected from patients receiving methadone alone as the baseline before they were randomized to coadminister either 200 mg voriconazole twice daily (BID) (400-mg BID loading doses on the first day) (n = 16) or matching placebo (n = 7) for the next 5 days. Pharmacokinetic samples for methadone and voriconazole were collected on the last day of voriconazole dosing. The safety data were collected throughout the study. Voriconazole increased the steady-state exposure of pharmacologically active enantiomer (R)-methadone: the mean area under the concentration-time curve from 0 to 24 h (AUC(0-24)) was increased by 47.2% (90% confidence intervals [CI]: 37.7%, 57.4%), and the mean peak concentration (C(max)) was increased by 30.7% (90% CI: 22.2%, 39.8%). The magnitude of increase in (S)-methadone exposure was greater than that of (R)-methadone: the AUC(0-24) was increased by 103.4% (90% CI: 85.0%, 123.6%), and the C(max) was increased by 65.4% (90% CI: 52.6%, 79.2%). Methadone appeared to have no effect on the steady-state voriconazole pharmacokinetics compared to the historical data for voriconazole alone. Methadone patients receiving voriconazole showed no signs or symptoms of significant opioid withdrawal or overdose. Coadministration of 200 mg voriconazole BID with methadone was generally safe and well tolerated. Nevertheless, caution should be exercised when voriconazole is coadministered with methadone due to the increase in (R)-methadone exposure, which in turn may require a dose reduction of methadone.


Subject(s)
Methadone/pharmacokinetics , Pyrimidines/pharmacokinetics , Triazoles/pharmacokinetics , Adult , Antifungal Agents/administration & dosage , Antifungal Agents/adverse effects , Antifungal Agents/pharmacokinetics , Area Under Curve , Back Pain/chemically induced , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Drug Interactions , Headache/chemically induced , Humans , Male , Metabolic Clearance Rate , Methadone/adverse effects , Methadone/therapeutic use , Middle Aged , Narcotics/administration & dosage , Narcotics/pharmacokinetics , Narcotics/therapeutic use , Opioid-Related Disorders/metabolism , Opioid-Related Disorders/rehabilitation , Pyrimidines/adverse effects , Sleep Initiation and Maintenance Disorders/chemically induced , Time Factors , Treatment Outcome , Triazoles/adverse effects , Voriconazole
5.
J Clin Pharmacol ; 45(12): 1373-82, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16291712

ABSTRACT

There is considerable interest in combining echinocandin and triazole antifungal agents for treatment of invasive fungal infections; however, information is needed regarding the tolerability and potential for pharmacokinetic interactions. Anidulafungin is a semisynthetic echinocandin, and voriconazole is an extended-spectrum triazole. In a random sequence, 17 subjects received anidulafungin with placebo, voriconazole with placebo, and anidulafungin with voriconazole. Anidulafungin was administered intravenously: 200 mg on day 1, then 100 mg/d on days 2 through 4. Voriconazole was administered orally: 400 mg every 12 hours on day 1, then 200 mg every 12 hours on days 2 to 4. No dose-limiting toxicities or serious adverse events occurred, and all adverse events were mild and consistent with the known safety profiles of both drugs. Pharmacokinetic parameters were not affected by coadministration. The geometric mean ratio (90% confidence interval) of the combination/drug alone for AUC(SS) was 97.4% (94.9-99.9), 97.4% (92.1-103.0), and 94.4% (87.0-102.5) for anidulafungin, voriconazole, and the voriconazole metabolite, respectively.


Subject(s)
Antifungal Agents/pharmacokinetics , Peptides, Cyclic/pharmacokinetics , Pyrimidines/pharmacokinetics , Triazoles/pharmacokinetics , Adult , Anidulafungin , Antifungal Agents/administration & dosage , Antifungal Agents/adverse effects , Cross-Over Studies , Drug Therapy, Combination , Echinocandins , Humans , Male , Peptides, Cyclic/administration & dosage , Peptides, Cyclic/adverse effects , Pyrimidines/administration & dosage , Pyrimidines/adverse effects , Triazoles/administration & dosage , Triazoles/adverse effects , Voriconazole
SELECTION OF CITATIONS
SEARCH DETAIL
...